Psoriasis is a chronic, inflammatory multisystem disease that affects up to 3.2% of the US
population. This guideline addresses important clinical questions that arise in psoriasis …

Objective To provide primary care clinicians with an up-to-date and practical overview of the
diagnosis and management of psoriasis. Quality of evidence PubMed, MEDLINE, EMBASE …

Background In a phase 2 study, the inhibition of the interleukin-17A receptor improved signs
and symptoms of psoriatic arthritis. We sought to evaluate the efficacy and safety of …

Background Ixekizumab is a humanised monoclonal antibody against the proinflammatory
cytokine interleukin 17A. We report two studies of ixekizumab compared with placebo or …

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with
awareness and attention to comorbidities - ScienceDirect Skip to main contentSkip to article …

Background Secukinumab, a fully human anti–interleukin-17A monoclonal antibody, has
demonstrated efficacy and safety in patients with moderate to severe plaque psoriasis …

Psoriatic arthritis (PsA) is a chronic, systemic inflammatory disease. Up to 40% of patients
with psoriasis will go on to develop PsA, usually within 5–10 years of cutaneous disease …

Psoriasis is a chronic, immune‐mediated disease affecting more than 100 million people
worldwide and up to 2.2% of the UK population. The aetiology of psoriasis is thought to …

Transdermal drug delivery systems have been around for decades, and current
technologies (eg, patches, ointments, and creams) enhance the skin permeation of low …

Background An urgent need exists in the United States to establish treatment goals in
psoriasis. Objective We aim to establish defined treatment targets toward which clinicians …